Sign up USA
Proactive Investors - Run By Investors For Investors

M Pharma predicts spate of product launches will lead to dramatic rise in revenues

The company has begun commercial discussions with multiple partners in the Eastern European community), Mexico, Brazil and Australia
Rising sales
M Pharma has plans to launch multiple new branded products in numerous North American sales channels this year

Shares in M Pharmaceutical Inc (CNSX:MQ, OTCMKTS:MPHMF) shot up on Friday morning as the drugs developer raised revenue guidance for this quarter and the next.

Having looked at the order books and factoring in planned product launches from its established distribution partners, including branded product launches in the USA and Canada, plus sales to new distribution/marketing partners outside of North America, M felt confident enough to predict a dramatic increase in revenues for next year and beyond.

M Pharma was recently informed that one of its customers has received new product approvals in new foreign markets, both in the Americas and in Asia, and will be launching operations in those markets in the third quarter and fourth quarter of 2017.

READ M Pharma completes 40J's acquisition on schedule

READ M Pharmaceutical piecing together the jigsaw of success

In addition to the expansion into new markets, M Pharma is in late-stage discussions with some current business partners for the sale of newly developed topical formulations of its menthol and L-arginine technology, in multiple topical formats (e.g. skin patches) for a variety of treatment conditions.

Lastly, M Pharma said it would be renewing its push to be more integrated with the current distribution partners in their marketing and sales initiatives, road shows, sales meetings, distributor events, and other means to help drive sales of M Pharma technologies.

M Pharma has plans to launch multiple new branded products in numerous sales channels in the United States and Canadian markets in the third quarter and fourth quarter of 2017, with additional product line launches in 2018 to advance top-line revenues and profitability.

These multiple pipeline products were acquired from 40J's LLC earlier this year and represent only a sample of the technologies currently working their way to commercialization, the company said.

Shares in M Pharma were up by a fifth to C$0.06 in lunchtime trading.

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
mri scanner
June 06 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use